Cerebrolysin for Vascular Dementia & Neuroprotection (NOT FDA-Approved) — Brain
Porcine-derived neuropeptide complex approved in 44-50 countries but NOT FDA-approved. Best evidence for vascular dementia; NO benefit shown for stroke. Requires IV infusion.
Overview
Cerebrolysin is a porcine-derived neuropeptide preparation containing BDNF, NGF, GDNF, CNTF-like peptides, plus tubulin, actin, and myelin basic protein fragments. REGULATORY: Approved in 44-50 countries (Russia, China, Germany, Austria, South Korea) but NOT FDA-approved in the United States despite 40+ years of use. BEST EVIDENCE: Vascular dementia - Cochrane 2019 review (6 studies, 597 patients) found beneficial effect but rated 'very low-quality evidence' due to high bias risk. Large Russian RCT (n=242) showed significant cognitive improvement. STROKE: NO clear benefit; increased adverse events requiring hospitalization reported. ALZHEIMER'S: Limited/mixed results. MS: ONE small trial (n=40) showed positive results. LIMITATIONS: All studies industry-funded, geographically concentrated in Russia/China, small effect sizes that 'may be too small to be clinically meaningful' (Cochrane). Requires IV infusion (impractical for many). Better evidence than BPC-157/TB-500/Dihexa but weaker than FDA-approved therapies.
Indications
- Vascular dementia (BEST EVIDENCE - moderate, Cochrane 'very low-quality')
- Alzheimer's disease (LIMITED/MIXED results from RCTs)
- Stroke recovery (⚠️ NO CLEAR BENEFIT - safety concerns noted)
- Traumatic brain injury (limited evidence)
- Multiple sclerosis (ONE small trial, n=40, positive results)
- Age-related cognitive decline (no prevention studies exist)
- General cognitive enhancement in healthy adults (ZERO studies)
Mechanism of Action
Brain injury, neuronal death, or neurodegenerative disease impairs cognitive and motor function
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Cerebrolysin | 30-50 mL diluted in saline | Daily for 10-21 days | Acute stroke protocol, administered in clinical setting |
| Cerebrolysin | 30-50 mL diluted in saline | Daily for 10-21 days, then maintenance | Post-TBI recovery protocol |
| Cerebrolysin | 10-30 mL diluted in saline | 2-3x weekly for 4-12 weeks | For cognitive decline, dementia, or nootropic use |
| Cerebrolysin | 5-10 mL | 2-3x weekly | Long-term maintenance for neurodegenerative conditions |
| Cerebrolysin | 20 mL diluted in 200 mL saline | Daily for 10 days post-methylprednisolone | RCT protocol (PMID: 28139626) for remitting MS in relapse regression |
Evidence Grade
GRADE C
Safety & Contraindications
- ✅ 40+ years of clinical use in multiple countries - generally well-tolerated
- ⚠️ NOT FDA-approved despite decades of availability - never passed US regulatory review
- Most common AEs: Vertigo, agitation, feeling hot, nausea, dizziness, headache, sweating
- ⚠️ STROKE: Increased adverse events requiring hospitalization reported
- Contraindicated in epilepsy, kidney disease, or hypersensitivity to constituents
- Requires IV infusion in medical setting - impractical for regular use
- All supporting clinical studies are industry-funded (bias concern)
- Geographic concentration of studies: Russia, China, Romania (5/6 Cochrane studies)